Safety and Immunogenicity of Pfs25-EPA/Alhydrogel®, a Transmission Blocking Vaccine against Plasmodium falciparum: An Open Label Study in Malaria Naïve Adults.
Transmission-blocking vaccines (TBVs) that target sexual stage parasite development could be an integral part of measures for malaria elimination. Pfs25 is a leading TBV candidate, and previous studies conducted in animals demonstrated an improvement of its functional immunogenicity after conjugatio...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2016-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC5066979?pdf=render |
| _version_ | 1818581699571744768 |
|---|---|
| author | Kawsar R Talaat Ruth D Ellis Janet Hurd Autumn Hentrich Erin Gabriel Noreen A Hynes Kelly M Rausch Daming Zhu Olga Muratova Raul Herrera Charles Anderson David Jones Joan Aebig Sarah Brockley Nicholas J MacDonald Xiaowei Wang Michael P Fay Sara A Healy Anna P Durbin David L Narum Yimin Wu Patrick E Duffy |
| author_facet | Kawsar R Talaat Ruth D Ellis Janet Hurd Autumn Hentrich Erin Gabriel Noreen A Hynes Kelly M Rausch Daming Zhu Olga Muratova Raul Herrera Charles Anderson David Jones Joan Aebig Sarah Brockley Nicholas J MacDonald Xiaowei Wang Michael P Fay Sara A Healy Anna P Durbin David L Narum Yimin Wu Patrick E Duffy |
| author_sort | Kawsar R Talaat |
| collection | DOAJ |
| description | Transmission-blocking vaccines (TBVs) that target sexual stage parasite development could be an integral part of measures for malaria elimination. Pfs25 is a leading TBV candidate, and previous studies conducted in animals demonstrated an improvement of its functional immunogenicity after conjugation to EPA, a recombinant, detoxified ExoProtein A from Pseudomonas aeruginosa. In this report, we describe results of an open-label, dose-escalating Phase 1 trial to assess the safety and immunogenicity of Pfs25-EPA conjugates formulated with Alhydrogel®. Thirty malaria-naïve healthy adults received up to four doses of the conjugate vaccine, with 8, 16, or 47 μg of conjugated Pfs25 mass, at 0, 2, 4, and 10 months. Vaccinations were generally well tolerated. The majority of solicited adverse events were mild in severity with pain at the injection site the most common complaint. Anemia was the most common laboratory abnormality, but was considered possibly related to the study in only a minority of cases. No vaccine-related serious adverse events occurred. The peak geometric mean anti-Pfs25 antibody level in the highest dose group was 88 (95% CI 53, 147) μg/mL two weeks after the 4th vaccination, and declined to near baseline one year later. Antibody avidity increased over successive vaccinations. Transmission blocking activity demonstrated in a standard membrane feeding assay (SMFA) also increased from the second to the third dose, and correlated with antibody titer and, after the final dose, with antibody avidity. These results support the further evaluation of Pfs25-EPA/Alhydrogel® in a malaria-endemic population. |
| first_indexed | 2024-12-16T07:37:39Z |
| format | Article |
| id | doaj.art-93a3af0304db4dbb8a1f1800b018de1b |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-16T07:37:39Z |
| publishDate | 2016-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-93a3af0304db4dbb8a1f1800b018de1b2022-12-21T22:39:11ZengPublic Library of Science (PLoS)PLoS ONE1932-62032016-01-011110e016314410.1371/journal.pone.0163144Safety and Immunogenicity of Pfs25-EPA/Alhydrogel®, a Transmission Blocking Vaccine against Plasmodium falciparum: An Open Label Study in Malaria Naïve Adults.Kawsar R TalaatRuth D EllisJanet HurdAutumn HentrichErin GabrielNoreen A HynesKelly M RauschDaming ZhuOlga MuratovaRaul HerreraCharles AndersonDavid JonesJoan AebigSarah BrockleyNicholas J MacDonaldXiaowei WangMichael P FaySara A HealyAnna P DurbinDavid L NarumYimin WuPatrick E DuffyTransmission-blocking vaccines (TBVs) that target sexual stage parasite development could be an integral part of measures for malaria elimination. Pfs25 is a leading TBV candidate, and previous studies conducted in animals demonstrated an improvement of its functional immunogenicity after conjugation to EPA, a recombinant, detoxified ExoProtein A from Pseudomonas aeruginosa. In this report, we describe results of an open-label, dose-escalating Phase 1 trial to assess the safety and immunogenicity of Pfs25-EPA conjugates formulated with Alhydrogel®. Thirty malaria-naïve healthy adults received up to four doses of the conjugate vaccine, with 8, 16, or 47 μg of conjugated Pfs25 mass, at 0, 2, 4, and 10 months. Vaccinations were generally well tolerated. The majority of solicited adverse events were mild in severity with pain at the injection site the most common complaint. Anemia was the most common laboratory abnormality, but was considered possibly related to the study in only a minority of cases. No vaccine-related serious adverse events occurred. The peak geometric mean anti-Pfs25 antibody level in the highest dose group was 88 (95% CI 53, 147) μg/mL two weeks after the 4th vaccination, and declined to near baseline one year later. Antibody avidity increased over successive vaccinations. Transmission blocking activity demonstrated in a standard membrane feeding assay (SMFA) also increased from the second to the third dose, and correlated with antibody titer and, after the final dose, with antibody avidity. These results support the further evaluation of Pfs25-EPA/Alhydrogel® in a malaria-endemic population.http://europepmc.org/articles/PMC5066979?pdf=render |
| spellingShingle | Kawsar R Talaat Ruth D Ellis Janet Hurd Autumn Hentrich Erin Gabriel Noreen A Hynes Kelly M Rausch Daming Zhu Olga Muratova Raul Herrera Charles Anderson David Jones Joan Aebig Sarah Brockley Nicholas J MacDonald Xiaowei Wang Michael P Fay Sara A Healy Anna P Durbin David L Narum Yimin Wu Patrick E Duffy Safety and Immunogenicity of Pfs25-EPA/Alhydrogel®, a Transmission Blocking Vaccine against Plasmodium falciparum: An Open Label Study in Malaria Naïve Adults. PLoS ONE |
| title | Safety and Immunogenicity of Pfs25-EPA/Alhydrogel®, a Transmission Blocking Vaccine against Plasmodium falciparum: An Open Label Study in Malaria Naïve Adults. |
| title_full | Safety and Immunogenicity of Pfs25-EPA/Alhydrogel®, a Transmission Blocking Vaccine against Plasmodium falciparum: An Open Label Study in Malaria Naïve Adults. |
| title_fullStr | Safety and Immunogenicity of Pfs25-EPA/Alhydrogel®, a Transmission Blocking Vaccine against Plasmodium falciparum: An Open Label Study in Malaria Naïve Adults. |
| title_full_unstemmed | Safety and Immunogenicity of Pfs25-EPA/Alhydrogel®, a Transmission Blocking Vaccine against Plasmodium falciparum: An Open Label Study in Malaria Naïve Adults. |
| title_short | Safety and Immunogenicity of Pfs25-EPA/Alhydrogel®, a Transmission Blocking Vaccine against Plasmodium falciparum: An Open Label Study in Malaria Naïve Adults. |
| title_sort | safety and immunogenicity of pfs25 epa alhydrogel r a transmission blocking vaccine against plasmodium falciparum an open label study in malaria naive adults |
| url | http://europepmc.org/articles/PMC5066979?pdf=render |
| work_keys_str_mv | AT kawsarrtalaat safetyandimmunogenicityofpfs25epaalhydrogelatransmissionblockingvaccineagainstplasmodiumfalciparumanopenlabelstudyinmalarianaiveadults AT ruthdellis safetyandimmunogenicityofpfs25epaalhydrogelatransmissionblockingvaccineagainstplasmodiumfalciparumanopenlabelstudyinmalarianaiveadults AT janethurd safetyandimmunogenicityofpfs25epaalhydrogelatransmissionblockingvaccineagainstplasmodiumfalciparumanopenlabelstudyinmalarianaiveadults AT autumnhentrich safetyandimmunogenicityofpfs25epaalhydrogelatransmissionblockingvaccineagainstplasmodiumfalciparumanopenlabelstudyinmalarianaiveadults AT eringabriel safetyandimmunogenicityofpfs25epaalhydrogelatransmissionblockingvaccineagainstplasmodiumfalciparumanopenlabelstudyinmalarianaiveadults AT noreenahynes safetyandimmunogenicityofpfs25epaalhydrogelatransmissionblockingvaccineagainstplasmodiumfalciparumanopenlabelstudyinmalarianaiveadults AT kellymrausch safetyandimmunogenicityofpfs25epaalhydrogelatransmissionblockingvaccineagainstplasmodiumfalciparumanopenlabelstudyinmalarianaiveadults AT damingzhu safetyandimmunogenicityofpfs25epaalhydrogelatransmissionblockingvaccineagainstplasmodiumfalciparumanopenlabelstudyinmalarianaiveadults AT olgamuratova safetyandimmunogenicityofpfs25epaalhydrogelatransmissionblockingvaccineagainstplasmodiumfalciparumanopenlabelstudyinmalarianaiveadults AT raulherrera safetyandimmunogenicityofpfs25epaalhydrogelatransmissionblockingvaccineagainstplasmodiumfalciparumanopenlabelstudyinmalarianaiveadults AT charlesanderson safetyandimmunogenicityofpfs25epaalhydrogelatransmissionblockingvaccineagainstplasmodiumfalciparumanopenlabelstudyinmalarianaiveadults AT davidjones safetyandimmunogenicityofpfs25epaalhydrogelatransmissionblockingvaccineagainstplasmodiumfalciparumanopenlabelstudyinmalarianaiveadults AT joanaebig safetyandimmunogenicityofpfs25epaalhydrogelatransmissionblockingvaccineagainstplasmodiumfalciparumanopenlabelstudyinmalarianaiveadults AT sarahbrockley safetyandimmunogenicityofpfs25epaalhydrogelatransmissionblockingvaccineagainstplasmodiumfalciparumanopenlabelstudyinmalarianaiveadults AT nicholasjmacdonald safetyandimmunogenicityofpfs25epaalhydrogelatransmissionblockingvaccineagainstplasmodiumfalciparumanopenlabelstudyinmalarianaiveadults AT xiaoweiwang safetyandimmunogenicityofpfs25epaalhydrogelatransmissionblockingvaccineagainstplasmodiumfalciparumanopenlabelstudyinmalarianaiveadults AT michaelpfay safetyandimmunogenicityofpfs25epaalhydrogelatransmissionblockingvaccineagainstplasmodiumfalciparumanopenlabelstudyinmalarianaiveadults AT saraahealy safetyandimmunogenicityofpfs25epaalhydrogelatransmissionblockingvaccineagainstplasmodiumfalciparumanopenlabelstudyinmalarianaiveadults AT annapdurbin safetyandimmunogenicityofpfs25epaalhydrogelatransmissionblockingvaccineagainstplasmodiumfalciparumanopenlabelstudyinmalarianaiveadults AT davidlnarum safetyandimmunogenicityofpfs25epaalhydrogelatransmissionblockingvaccineagainstplasmodiumfalciparumanopenlabelstudyinmalarianaiveadults AT yiminwu safetyandimmunogenicityofpfs25epaalhydrogelatransmissionblockingvaccineagainstplasmodiumfalciparumanopenlabelstudyinmalarianaiveadults AT patrickeduffy safetyandimmunogenicityofpfs25epaalhydrogelatransmissionblockingvaccineagainstplasmodiumfalciparumanopenlabelstudyinmalarianaiveadults |